Skip to main content

Table 2 Binary logistic regression analysis for sorafenib response

From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

Variable   Univariate analysis Multivariate analysis
  OR (95% CI) P OR (95% CI) P
Age (year)   0.994 (0.963–1.027) 0.719   
Sex (Female) 0.570 (0.203–1.603) 0.287   
Body mass index (kg/m2)   0.885 (0.783–1.000) 0.050   
ECOG PS (1 vs. 0) 3.000 (0.627–14.358) 0.169   
Etiology HCV vs. nonviral 0.440 (0.167–1.16) 0.097 0.612 (0.179–2.088) 0.433
  HBV vs. nonviral 0.200 (0.055–0.722) 0.014 0.133 (0.027–0.666) 0.014
Ascites 2 vs. 1 2.333 (0.473–11.506) 0.298   
Platelet (×103/μL)   1.006 (1.001–1.011) 0.017 1.005 (0.999–1.011) 0.103
Creatinine (mg/dL)   1.115 (0.529–2.348) 0.775   
Albumin (g/dL)   1.168 (0.488–2.794) 0.727   
Total bilirubin (mg/dL)   1.541 (0.698–3.405) 0.285   
Prothrombin time (INR)   6.922 (0.164–291.871) 0.311   
MELD   1.208 (0.937–1.558) 0.145   
Macrovascular invasion   1.615 (0.71–3.677) 0.253   
Extrahepatic spread   1.506 (0.708–3.205) 0.288   
BCLC stage B vs. A 1.000 (0.315–3.174) 1.000 0.808 (0.203–3.224) 0.763
  C vs. A 2.895 (1.002–8.364) 0.050 3.476 (0.987–12.243) 0.052
Log AFP (ng/dL)   1.013 (0.779–1.317) 0.925   
Log PIVKA-II (mAU/mL)   1.989 (1.359–2.911) < 0.001 1.724 (1.124–2.644) 0.013
Log Angiopoietin 2 (ng/mL)   3.754 (0.534–26.374) 0.183   
Log CD117 (ng/mL)   2.895 (0.612–13.687) 0.18   
bFGF (pg/mL)   1.321 (1.092–1.598) 0.004 1.326 (1.077–1.634) 0.008
Log HGF (pg/mL)   16.534 (1.275–214.349) 0.032 23.438 (0.750–732.109) 0.072
LOXL2 (ng/mL)   0.769 (0.533–1.11) 0.160   
Log sVEGFR1 (ng/mL)   0.272 (0.047–1.592) 0.149   
AAR   1.373 (0.84–2.246) 0.206   
APRI   0.971 (0.718–1.314) 0.85   
FIB4   0.926 (0.842–1.02) 0.12   
Lok index   0.722 (0.154–3.386) 0.68   
P2/MS   1.004 (0.998–1.01) 0.179   
  1. Abbreviations: OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4